Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
Indorf P, Kubitza C, Scheidig AJ, Kunze T, Clement B.
J Med Chem · journal article · DOI 10.1021/acs.jmedchem.9b01483 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för epacadostat. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
50 träffar<i>N</i>-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase.
Yang D, Zhang S, Fang X, Guo L, Hu N, Guo Z, Li X, Yang S, He JC, Kuang C, Yang Q.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b01079Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.
Zou Y, Hu Y, Ge S, Zheng Y, Li Y, Liu W, Guo W, Zhang Y, Xu Q, Lai Y.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111750Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.
Du Q, Feng X, Wang Y, Xu X, Zhang Y, Qu X, Li Z, Bian J.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111629Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.
Chen S, Guo W, Liu X, Sun P, Wang Y, Ding C, Meng L, Zhang A.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.06.037Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Hu H, Li M, Wu D, Li Z, Miao R, Liu Y, Gong P.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.05.048Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors.
Yang X, Cai S, Liu X, Chen P, Zhou J, Zhang H.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.03.0054,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L, Chen Y, He J, Njoya EM, Chen J, Liu S, Xie C, Huang W, Wang F, Wang Z, Li Y, Qian S.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.02.014Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.
Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP.
Eur J Med Chem · research-article; journal article · DOI 10.1016/j.ejmech.2018.11.010Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives.
Zhang S, Qi F, Fang X, Yang D, Hu H, Huang Q, Kuang C, Yang Q.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.10.017Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
Pan L, Zheng Q, Chen Y, Yang R, Yang Y, Li Z, Meng X.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.08.013Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
Fang K, Dong G, Li Y, He S, Wu Y, Wu S, Wang W, Sheng C.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.7b00487A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies.
Griglio A, Torre E, Serafini M, Bianchi A, Schmid R, Coda Zabetta G, Massarotti A, Sorba G, Pirali T, Fallarini S.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2018.01.032Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.
Brant MG, Goodwin-Tindall J, Stover KR, Stafford PM, Wu F, Meek AR, Schiavini P, Wohnig S, Weaver DF.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.7b00488Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
Weng T, Qiu X, Wang J, Li Z, Bian J.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2017.11.088INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Yue EW, Sparks R, Polam P, Modi D, Douty B, Wayland B, Glass B, Takvorian A, Glenn J, Zhu W, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Emm T, Scherle PA, Metcalf B, Combs AP.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.6b00391New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation.
Coluccia A, Passacantilli S, Famiglini V, Sabatino M, Patsilinakos A, Ragno R, Mazzoccoli C, Sisinni L, Okuno A, Takikawa O, Silvestri R, La Regina G.
J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b00718Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties.
Qian S, He T, Wang W, He Y, Zhang M, Yang L, Li G, Wang Z.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2016.10.003Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Dounay AB, Tuttle JB, Verhoest PR.
J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.5b00461Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.5b00326